vs

Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and Cellectis S.A. (CLLS). Click either name above to swap in a different company.

CF BANKSHARES INC. is the larger business by last-quarter revenue ($15.7M vs $9.5M, roughly 1.7× Cellectis S.A.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs -265.9%, a 305.9% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 12.6%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $18.2M).

CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

CFBK vs CLLS — Head-to-Head

Bigger by revenue
CFBK
CFBK
1.7× larger
CFBK
$15.7M
$9.5M
CLLS
Growing faster (revenue YoY)
CLLS
CLLS
+362.3% gap
CLLS
375.0%
12.6%
CFBK
Higher net margin
CFBK
CFBK
305.9% more per $
CFBK
40.0%
-265.9%
CLLS
More free cash flow
CLLS
CLLS
$9.4M more FCF
CLLS
$27.6M
$18.2M
CFBK

Income Statement — Q4 FY2025 vs Q2 FY2024

Metric
CFBK
CFBK
CLLS
CLLS
Revenue
$15.7M
$9.5M
Net Profit
$5.7M
$-25.3M
Gross Margin
Operating Margin
43.4%
-181.1%
Net Margin
40.0%
-265.9%
Revenue YoY
12.6%
375.0%
Net Profit YoY
29.9%
-51.9%
EPS (diluted)
$0.88
$-0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CFBK
CFBK
CLLS
CLLS
Q4 25
$15.7M
Q3 25
$15.5M
Q2 25
$15.6M
Q1 25
$14.1M
Q4 24
$14.0M
Q3 24
$13.1M
Q2 24
$12.6M
$9.5M
Q1 24
$12.2M
Net Profit
CFBK
CFBK
CLLS
CLLS
Q4 25
$5.7M
Q3 25
$2.3M
Q2 25
$5.0M
Q1 25
$4.4M
Q4 24
$4.4M
Q3 24
$4.2M
Q2 24
$1.7M
$-25.3M
Q1 24
$3.1M
Operating Margin
CFBK
CFBK
CLLS
CLLS
Q4 25
43.4%
Q3 25
17.5%
Q2 25
41.1%
Q1 25
39.5%
Q4 24
36.9%
Q3 24
40.4%
Q2 24
15.4%
-181.1%
Q1 24
30.9%
Net Margin
CFBK
CFBK
CLLS
CLLS
Q4 25
40.0%
Q3 25
15.1%
Q2 25
32.3%
Q1 25
31.4%
Q4 24
35.2%
Q3 24
32.2%
Q2 24
13.5%
-265.9%
Q1 24
25.2%
EPS (diluted)
CFBK
CFBK
CLLS
CLLS
Q4 25
$0.88
Q3 25
$0.36
Q2 25
$0.77
Q1 25
$0.68
Q4 24
$0.68
Q3 24
$0.65
Q2 24
$0.26
$-0.28
Q1 24
$0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CFBK
CFBK
CLLS
CLLS
Cash + ST InvestmentsLiquidity on hand
$259.0M
$149.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$184.4M
$148.6M
Total Assets
$2.1B
$407.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CFBK
CFBK
CLLS
CLLS
Q4 25
$259.0M
Q3 25
$272.4M
Q2 25
$275.7M
Q1 25
$241.0M
Q4 24
$235.3M
Q3 24
$233.5M
Q2 24
$241.8M
$149.0M
Q1 24
$236.9M
Stockholders' Equity
CFBK
CFBK
CLLS
CLLS
Q4 25
$184.4M
Q3 25
$179.3M
Q2 25
$177.0M
Q1 25
$172.7M
Q4 24
$168.4M
Q3 24
$164.0M
Q2 24
$159.6M
$148.6M
Q1 24
$158.0M
Total Assets
CFBK
CFBK
CLLS
CLLS
Q4 25
$2.1B
Q3 25
$2.1B
Q2 25
$2.1B
Q1 25
$2.1B
Q4 24
$2.1B
Q3 24
$2.1B
Q2 24
$2.0B
$407.1M
Q1 24
$2.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CFBK
CFBK
CLLS
CLLS
Operating Cash FlowLast quarter
$18.7M
$28.9M
Free Cash FlowOCF − Capex
$18.2M
$27.6M
FCF MarginFCF / Revenue
115.6%
290.5%
Capex IntensityCapex / Revenue
3.1%
13.2%
Cash ConversionOCF / Net Profit
3.26×
TTM Free Cash FlowTrailing 4 quarters
$33.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CFBK
CFBK
CLLS
CLLS
Q4 25
$18.7M
Q3 25
$5.5M
Q2 25
$8.0M
Q1 25
$2.2M
Q4 24
$14.2M
Q3 24
$-1.3M
Q2 24
$4.0M
$28.9M
Q1 24
$-1.2M
Free Cash Flow
CFBK
CFBK
CLLS
CLLS
Q4 25
$18.2M
Q3 25
$5.2M
Q2 25
$7.8M
Q1 25
$2.2M
Q4 24
$13.9M
Q3 24
$-1.3M
Q2 24
$4.0M
$27.6M
Q1 24
$-1.2M
FCF Margin
CFBK
CFBK
CLLS
CLLS
Q4 25
115.6%
Q3 25
33.6%
Q2 25
50.3%
Q1 25
15.2%
Q4 24
99.6%
Q3 24
-9.9%
Q2 24
31.6%
290.5%
Q1 24
-9.5%
Capex Intensity
CFBK
CFBK
CLLS
CLLS
Q4 25
3.1%
Q3 25
1.7%
Q2 25
0.7%
Q1 25
0.4%
Q4 24
1.9%
Q3 24
0.2%
Q2 24
0.1%
13.2%
Q1 24
0.0%
Cash Conversion
CFBK
CFBK
CLLS
CLLS
Q4 25
3.26×
Q3 25
2.34×
Q2 25
1.58×
Q1 25
0.50×
Q4 24
3.21×
Q3 24
-0.30×
Q2 24
2.35×
Q1 24
-0.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons